The molecular mechanisms influencing muscle atrophy in humans are poorly understood. Atrogin-1 and MuRF1, two ubiquitin E3-ligases, mediate rodent and cell muscle atrophy and are suggested to be regulated by an Akt/Forkhead (FKHR) signaling pathway. Here we investigated the expression of atrogin-1, MuRF1, and the activity of Akt and its catabolic (FKHR and FKHRL1) and anabolic (p70 s6k and GSK-3β) targets in human skeletal muscle atrophy. The muscle atrophy model used was amyotrophic lateral sclerosis (ALS). All measurements were performed in biopsies from 22 ALS patients and 16 healthy controls as well as in G93A ALS mice. ALS patients had a significant increase in atrogin-1 mRNA and protein content, which was associated with a decrease in Akt activity. There was no difference in the mRNA and protein content of FKHR, FKHRL1, p70 s6k , and GSK-3β. Similar observations were made in the G93A ALS mice. Human skeletal muscle atrophy, as seen in the ALS model, is associated with an increase in atrogin-1 and a decrease in Akt. The transcriptional regulation of human atrogin-1 may be controlled by an Akt-mediated transcription factor other than FKHR or via another signaling pathway.
Studies in cellular and rodent models of muscle atrophy, using pharmacological and/or gene inhibition techniques, have suggested that the transcriptional regulation of atrogin-1 and MuRF1 is controlled by an Akt/Forkhead (FKHR)-dependent signaling pathway (9, 12, 13) . Akt, also called PKB (protein kinase B), was originally seen as an activator of skeletal muscle hypertrophy as it participates in the indirect control of p70 S6K and PHAS-1/4E-BP1 and in the direct control of glycogen synthase kinase-3β (GSK-3β), factors that positively regulate translation initiation and protein synthesis (14) (15) (16) (17) (18) (19) . Additionally, it has been well documented that active Akt also phosphorylates and inhibits the transcriptional activity of FKHR (foxo1) and FKHRL1 (foxo3) by their sequestration to the cytosol (20) (21) (22) . At present it is unknown whether human skeletal muscle atrophy is associated with a reduced Akt activity and consequently an increase in nuclear FKHR and/or FKHRL1 and/or decreases in p70 S6K and GSK-3β. Furthermore, it is not known whether alterations in Akt/FKHR signaling are associated with changes in atrogin-1 mRNA and protein levels in human skeletal muscle atrophy.
The aim of the present study was to measure and compare the skeletal muscle expression of the ubiquitin E3 ligases, atrogin-1 and MuRF1, as well as Akt and several of its downstream targets, such as FKHR, FKHRL1, phosphorylated p70 S6K , and phosphorylated GSK-3β in a model of human skeletal muscle atrophy. The skeletal muscle atrophy model used was ALS, a progressive neurodegenerative disease characterized by the loss of both upper and lower motor neurons, which leads to severe muscle weakness and atrophy (23) . Because the majority of previous studies investigating these muscle atrophy targets have been performed in rodents, we also investigated these targets in a transgenic mouse model of ALS, overexpressing mutant SOD1 (G93A), to establish whether similarities occur within the same human and rodent skeletal muscle atrophy model. Based on rodent and cell models of skeletal muscle atrophy, we hypothesized that human skeletal muscle atrophy would present an increase in atrogin-1, MuRF1, nuclear FKHR, and FKHRL1 and a decrease in phosphorylated Akt, p70 S6K , and GSK-3β.
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MATERIALS AND METHODS
Subjects
Skeletal muscle biopsies were obtained from 22 patients (16 males, 6 females; age range 33-79 years; mean age 57 years) diagnosed with ALS. The routine histochemical analysis of all biopsies revealed a neurogenic pattern ranging from mild to severe. At the time of the biopsy, the duration of illness was 3-48 months. In all cases, conduction blocks were excluded by sensorimotor nerve conduction studies; laboratory tests ruled out dysproteinemia, hexoaminidase A deficiency, anti-GM1 antibodies, and thyroid and parathyroid disorders. Sixteen age-matched healthy subjects (13 males, 3 females; age range 29-73 years; mean age 53 years) free from neuromuscular disorders were used as controls. The control subjects were not participating in regular physical activity programs. Subject details are shown in Table 1 . The research protocol was approved by the institutional ethics committee, and informed consent was obtained from all participants.
Muscle biopsies
For the ALS patients, biopsies were taken from either the biceps or vastus lateralis muscles, whereas for control subjects, biopsies were taken from vastus lateralis muscles. The biopsies were performed using a Bergstrom or open biopsy procedure, with the resultant collection of ~100-500 mg of muscle tissue. All biopsies were immediately frozen in liquid nitrogen and stored at -80°C until analyzed.
ALS mice
Transgenic mice carrying the SOD1 G93A mutation were obtained from Jackson Laboratories (Bar Harbor, ME). Comparison was made with animals with an overexpression of the wild-type human SOD1 gene (WT). Thirteen G93A and 10 WT mice were included in the study. Five G93A mice were killed at the age of 90 days (ALS 90) and all other animals were studied at the age of 120 days (ALS 120; WT 120). For the G93A ALS mice, 90 and 120 days correspond to ~65% and 85%, respectively, of their life expectancy. All mice were anesthetized by an i.p. infusion of pentobarbitone sodium (50 mg/kg body weight). The tibialis anterior muscle was carefully dissected and quickly frozen in liquid nitrogen and stored at -80°C.
Muscle fiber type, size, and atrophy index
For the human muscle samples, muscle fiber diameter and atrophy index were measured in routine ATPase-stained samples according to Dubowitz (24) . The upper limits for the value of atrophy for normal adult male muscle is 150 for type I and type II fibers and for female muscle 100 and 150 for type I and type II fibers, respectively, from the biceps, and 100 and 200 for type I and type II fibers, respectively, from the vastus lateralis (24) . Mean diameter and standard deviation were obtained from the measurement of 200 type I fibers and 200 type II fibers for each muscle biopsy using IMAGE software (Scion, Frederick, MD). In the ALS and control mice, muscle size of the tibialis anterior was determined as the wet weight of the entire muscle (25) .
RNA extraction and real-time quantitative PCR
RNA was extracted from human and mouse skeletal muscle using a commercially available preparation, peqGOLD Tri-Fast (Peqlab, Germany). Three micrograms of RNA were reverse transcribed to cDNA using Random Hexomer primers and a Stratascript enzyme (Stratagene, The Netherlands) while quantitative PCR was performed using an MX3000p thermal cycler system and Brilliant QPCR Master Mix or the Brilliant SYBER Green QPCR Master Mix (Stratagene) as published previously (26, 27) . The PCR conditions for the genes amplified using the Brilliant QPCR Master Mix consisted of one denaturing cycle at 90°C for 10 min, followed by 40 cycles consisting of denaturing at 90°C for 30 s and annealing at 60°C for 60 s. The PCR conditions for the genes amplified using the Brilliant SYBER Green QPCR Master Mix consisted of one denaturing cycle at 90°C for 10 min, followed by 40 cycles consisting of denaturing at 90°C for 30 s, annealing at 60°C for 60 s and elongation at 72°C for 60 s. At the end of the PCR, the samples were subjected to a melting curve analysis. To control for any variations due to efficiencies of the reverse transcription and PCR, acidic ribosomal phosphoprotein PO (RPLPO or 36B4) was used as an internal control. All PCR runs were performed in triplicate. PCR primer and probe sequences are provided in Table 2 .
Protein extraction and Western blotting
Thirty milligrams of muscle were used for protein extraction as mentioned previously (28, 29) . Briefly, the muscle was homogenized, using a Polytron PT 2100 (Kinematica AG, Luzern, Switzerland), in 500 μl ice-cold buffer A (250 mM sucrose, 10 mm Tris, 10 mM NaCl, 3 mM MgCl 2 , 1 mM DTT, 2 μl each of phosphatase inhibitor cocktails I and II and protease inhibitor cocktail) (Sigma, St. Louis, MO). The homogenate was subjected to centrifugation for 5 min at 500g at 4°C. The supernatant, representing a crude cytosolic fraction, was removed and stored at -20°C until required for later analysis. The remaining pellet was resuspended in 500 μl in icecold buffer B (50 mM Tris, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 50 mM MgCl 2 , 50 mM NaF, 5 mM Na pyrophosphate, 1 mM DTT, 1 mM PMSF, 2 μl protease inhibitor cocktail II) (Sigma) and placed on ice for 10 min with occasional agitation. The suspension was then subjected to centrifugation for 5 min at 3000g at 4°C. Following this centrifugation, the remaining supernatant was then removed, representing the nuclear fraction. Protein content was determined using the method of Lowry (Lowry et al., 1972). Electrophoresis was performed using 10-12% SDS-PAGE gels in cold (4°C) buffer containing 25 mM Tris, pH 8.8, 192 mM glycine, and 10% methanol. After an overnight protein transfer, PVDF membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20, and thereafter antibody incubation was performed with gentle shaking at room temperature for 1 h. The membranes were then washed three times for 5 min with PBS containing 0.1% Tween-20, incubated for 1 h at room temperature with the secondary antibody, and again washed as previously mentioned. Finally, the membranes were treated for 5 min with chemiluminescence substrate (Amersham Biosciences, Otelfingen, Switzerland), and an X-ray film (Amersham Biosciences) was exposed to the PVDF membranes.
The polyclonal anti-atrogin-1 antibody (Eurogentec, Liège, Belgium) was raised against amino acids 303-316 (CYPRKEQYGDTLQL) of the human atrogin-1 protein (Swiss-Prot: Q969P5) and affinity purified. This sequence is also specific for the mouse atrogin-1 protein (Swiss-Prot: Q9CPU7). The specificity of the antibody was established by performing immunoblotting experiments with the preimmune serum, which resulted in no signal. Additionally, competition experiments were performed whereby the purified antibody was incubated with the immunizing peptide for 2 h at room temperature. After hybridizing the immunoblots with this peptideantibody complex, the signal observed with the anti-atrogin-1 antibody was completely removed. The other antibodies and their dilutions used in the present study include Akt1, phospho-Akt1 (ser473), phospho-GSK-3α/β (ser21/9), FKHR, FKHRL1, phospho-FKHR (ser256), all at 1:1000; phospho-FKHRL1 (ser253) and phospho-p70 S6 kinase (Thr389), both at 1:2000 (Cell Signaling Technology, Danvers, MA). The secondary antibodies used were goat anti-rabbit IgG (Cell Signaling Technology) and goat anti-mouse IgG (Bio-Rad, Reinach, Switzerland) conjugated to horseradish peroxidase. To control for protein content, all immunoblotting using cytosolic proteins was normalized with α-tubulin (1:10,000) (Sigma). For the immunoblots measuring the phospho-p70 S6 kinase, FKHR and the FKHRL1 protein contents in the nuclear fraction Lamin A (1:1000) (Chemicon, Temecula, CA) was used as the normalizing protein.
Statistics
Unpaired t tests were used to test for differences between the human ALS and the control groups. A one-way ANOVA with a Dunnett C post hoc test was used to test for differences between WT 120, ALS 90, and ALS 120 mice. A Pearson correlation coefficient was used to test the strength and relationship between variables. The level of significance was set at P < 0.05. Data are mean ± SE.
RESULTS
Skeletal muscle cross sectional area (CSA) of the type I and type II fibers was 35% (P=0.002) and 22% (P=0.03) smaller in the ALS when compared with the control subjects ( Table 3) . Calculation of the muscle atrophy index indicated that the skeletal muscle from ALS patients, when compared with the healthy control subjects, had muscle atrophy index values ~2 and threefold greater for the type I (P=0.03) and type II (P=0.006) fibers, respectively (Table 3 ). The muscle CSA and atrophy index values for the type I and type II fibers were not significantly different within the ALS or the control groups (P>0.05; data not shown). There were no significant correlations between the muscle CSA or the atrophy index values and any of the molecular measurements (data not shown). There was no difference in muscle fiber type composition between the ALS and control subjects, with both groups presenting 50.5% and 51.5%, respectively, for the type I fibers and 49.5% and 48.5%, respectively, for the type II fibers.
Atrogin-1 and MuRF1 have been suggested to be integral players in the skeletal muscle atrophy process. The skeletal muscle of the ALS patients, when compared with the healthy control subjects, showed a significant 170% and 340% increase in atrogin-1 mRNA and protein content, respectively (Fig. 1A, 1B) .
The G93A mice were killed at the age of 90 days (ALS 90) and 120 days (ALS 120). Wild-type mice were killed at 120 days (WT 120). The mass of the tibialis anterior muscle was ~44% and 58% lower in both the ALS 90 and ALS 120 mice, respectively, when compared with the WT 120 mice (P<0.001) (Fig. 2A) . The atrogin-1 mRNA contents in the ALS 90 and ALS 120 mice where significantly increased by 320% and 240%, respectively, when compared with WT 120 mice (Fig. 2B) . There was no difference in the muscle fiber sizes or in the atrogin-1 mRNA content in the ALS 90 when compared with the ALS 120 mice (P>0.05). When the mRNA results from all of the mice were pooled, there was a significant negative correlation (P=0.001, r=-0.70) between tibialis anterior mass and atrogin-1 content (Fig. 2C) . This correlation was not observed for the human subjects. The atrogin-1 protein content in the ALS 90 mice was significantly increased by 170% when compared with WT 120 mice (Fig. 2D) .
There was no difference in MuRF1 gene expression between the ALS and control subjects (P=0.44) (Fig. 3A) . The same was observed for the ALS mice (P=0.26) (Fig. 3B) . All mRNA measurements were normalized against RPLPO, which demonstrated a high degree of stability.
The RPLPO values for the control and ALS subjects were 6.8 ± 2.4 and 7.3 ± 2.4 A.U., respectively. The RPLPO values for the WT 120, ALS 90, and ALS 120 mice were 2.8 ± 0.2, 3.0 ± 0.6, and 2.2 ± 0.2 A.U, respectively.
Because the transcription of atrogin-1 has been suggested to be regulated via an Akt/FKHR pathway, we decided to measure Akt, FKHR (foxo1), and FKHRL1 (foxo3) levels in the skeletal muscle of the ALS patients and controls as well as in the G93A and wild-type mice. There was no difference in Akt, FKHR, and FKHRL1 mRNA levels in the ALS patients when compared with the control subjects (Table 4) . However, at the protein level, the ALS patients, when compared with the healthy control subjects, had a lower content of the active phosphorylated Akt protein as demonstrated by a significant (P=0.02) 68% decrease in the phosphorylated Akt (ser293)/total Akt ratio (Fig. 4A ). There was, however, no difference in the nuclear protein contents of FKHR or FKHRL1 between the ALS or the control patients (Fig. 4B, 4C ). The same observations were also made for phosphorylated Akt and the nuclear protein content of FKHRL1 in the G93A mice when compared with the wild-type mice (data not shown).
In addition to the inhibition of FKHR and FKHRL1 activities, Akt has been shown to have an anabolic effect by activating several downstream kinases responsible for protein translation initiation and protein synthesis. The reduced Akt activity in the ALS patients would suggest that they have a lower quantity of phosphorylated p70 s6k and a greater amount of GSK-3β, when compared with control subjects. There was, however, no difference in p70 s6k or GSK-3β mRNA and their phosphorylated protein contents in the ALS when compared with the control subjects ( Fig. 5A-D) .
DISCUSSION
The molecular targets and signaling pathways influencing human skeletal muscle atrophy are not well understood. In the present study, we investigated, for the first time in human skeletal muscle, the regulation of several catabolic and anabolic targets believed to be crucial in the atrophy and/or hypertrophy processes. We used ALS as a human model of skeletal muscle atrophy and made comparisons with healthy control subjects. Several novel and important findings were observed. First, we show that atrogin-1 mRNA and protein content is significantly increased in the skeletal muscle of ALS patients when compared with that of healthy control subjects. Second, we show that Akt activity is reduced in ALS patients. Third, although Akt activity was reduced, there was no difference in the nuclear protein content of FKHR and FKHRL1 between the control and ALS patients. These results were also observed in the atrophied skeletal muscle of transgenic ALS mice overexpressing the G93A mutation in the SOD1 gene.
Note that these results cannot be seen as being specific to the skeletal muscle atrophy observed in human or rodent ALS. However, the relevance of these results to ALS skeletal muscle atrophy should be mentioned. Although the initial skeletal muscle atrophy in ALS is a consequence of the degeneration in upper and lower motor neurons, local molecular signaling events may also play an important role in the muscle atrophy observed in ALS. This is supported by the previous observation in ALS patients of an increase in the protein content of the 26S proteasome (30) , an integral component of the ATP-ubiquitin-dependent proteolytic complex. This finding, in combination with our observation of an increase in the muscle-specific E3-ubiquitin ligase atrogin-1, suggests that the ATP-ubiquitin-dependent proteolytic system, may contribute to the skeletal muscle atrophy observed in ALS.
The observation that atrogin-1 was significantly increased in the atrophied skeletal muscle of ALS patients supports previous observations in cell and rodent models of muscle atrophy (5-9, 12, 13). Two previous studies have observed that atrogin-1 mRNA is increased in atrophied human skeletal muscle (10, 11) ; however, no measurements of the atrogin-1 protein were made in these studies. It appears that the increases in atrogin-1 mRNA result in an increase in the translation of the atrogin-1 protein. Intuitively, this suggests that atrogin-1 would play a significant role in muscle protein degradation via ubiquitin-dependent proteolysis.
MuRF1 is another muscle-specific ubiquitin E3-ligase. However, we did not observe any changes in its gene expression between the ALS and control subjects. It appears that human skeletal muscle atrophy is influenced more by atrogin-1 than by MuRF1. This observation has also been made following 2 wk of limb immobilization in humans (10) , another model of human skeletal muscle atrophy. However, several rodent and cell models of muscle atrophy, including immobilization, denervation, sepsis, incubation with dexamethasone, and exposure to H 2 O 2 and space flight, have all observed increases in MuRF1 mRNA (5, 7, 10, (31) (32) (33) (34) . The measurement of the MuRF1 protein should also be made when specific antibodies are available. At present, it is unknown whether MuRF1 plays a role in other models of human skeletal muscle atrophy.
We were also interested in identifying which signaling pathways may be responsible for the increase in atrogin-1 mRNA and protein levels in human skeletal muscle atrophy. Several studies investigating the transcriptional regulation of atrogin-1 have suggested that it is regulated via an Akt/FKHR pathway (9, 12, 13, 31) . It has been well documented that Akt can phosphorylate both FKHR and FKHRL1, resulting in their exclusion from the nucleus (35, 36) . However, in these pharmacological and genetic manipulation models of muscle atrophy, the phosphorylated active Akt protein was reduced while the FKHR and/or FKHRL1 translocation to the nucleus was increased. Once in the nucleus, FKHR and/or FKHRL1 binds to its forkhead element on the atrogin-1 promoter and increases atrogin-1 gene transcription (9, 12, 13, 31) . In support of these rodent models of skeletal muscle atrophy, we observed that Akt activity was significantly reduced in the human ALS model of skeletal muscle atrophy. A reduced Akt activity in the ALS patients would suggest that they have a greater nuclear protein content of the active nonphosphorylated forms of the FKHR and FKHRL1 proteins. Surprisingly, we did not observe any difference in the nuclear protein content of both FKHR and FKHRL1 in the ALS patients when compared with the control subjects. In the present study, the same results for Akt and FKHRL1 and atrogin-1 protein were also observed in the tibialis anterior muscle of SOD1 G93A transgenic mice. This demonstrates that the skeletal muscle atrophy signaling events occurring in both ALS patients and ALS transgenic mice are very similar. Whether or not the observations made in other rodent models of human skeletal muscle are similar to those observed in the actual human atrophy condition requires investigation.
It is well known that Akt is a powerful regulator of the FKHR family (20, 21) . However, our observation that the Akt/FKHR regulatory relationship did not follow its usual pattern is not without precedent. It has previously been observed, in human primary breast tumors, that in tumors lacking a detectable phosphorylated Akt protein, FKHRL1 was not increased in the nucleus but instead predominantly confined in the cytoplasm (37) . Therefore, it appears that under certain conditions, Akt and FKHR regulation seem to be independent of each other. Our findings suggest that, at least in the ALS model of human skeletal muscle atrophy, atrogin-1 regulation may not be via an Akt/FKHR pathway. Whether the same Akt/FKHR response is observed in other human models of muscle atrophy requires further investigation. It is possible that atrogin-1 may be regulated via another Akt-mediated transcription factor or via another signaling pathway altogether. Recent studies have suggested that atrogin-1 may be regulated via a tumor necrosis factor (TNF)-α/mitogen-activated protein kinase pathway in C2C12 cells stimulated with H 2 O 2 and TNF-α, in mice injected with recombinant TNF-α (38) , and in humans with acute quadriplegic myopathy (11); however, the responsible transcription factor was not identified.
Because Akt was reduced in the skeletal muscle of ALS patients, when compared with the control subjects, we also investigated whether there was a concomitant regulation of downstream Akt target proteins responsible for protein translation, initiation, and catabolism, such as p70 s6k (39, 40) and GSK-3β (15, 19) . Inhibition of Akt activity in myotubes blocks p70 s6k , resulting in a decrease in muscle hypertrophy and growth (41, 42) . Surprisingly, we did not observe any difference in p70 s6k between the ALS and control subjects. It has previously been shown that p70 s6k can also be activated directly by phosphoinositide-dependent protein kinase (PDK1) (43) , suggesting that Akt may be dispensable for signaling to p70 s6k . It is possible that p70 s6k activity is maintained by other mechanisms in an attempt to combat skeletal muscle atrophy. GSK-3β can be phosphorylated by Akt, which leads to its inhibition and a consequential increase in protein synthesis (15, 19) . Therefore, we expected a decrease in phosphorylated GSK-3β in the ALS patients when compared with the control subjects. However, as with p70 s6k , phosphorylated GSK-3β levels were not different between the two groups.
In conclusion, we show that human skeletal muscle atrophy, as seen in ALS, is associated with an increase in the muscle-specific ubiquitin-E3 ligase atrogin-1 and a decrease in active Akt. Interestingly, there was no effect on the nuclear content of FKHR and FKHRL1. These results suggest that the increase in atrogin-1 in human skeletal muscle atrophy, at least in ALS, is not via an Akt/FKHR-mediated pathway. In skeletal muscle atrophy, as seen in ALS, atrogin-1 may be regulated via another Akt-mediated transcription factor or via another signaling pathway. Whether the reduction in Akt signaling is directly involved in an increase in protein degradation in human skeletal muscle is yet to be determined. Although the content of phosphorylated Akt was lower in the ALS patients, there was no difference in the levels of p70 s6k or GSK-3β between the control and ALS subjects. Further investigations using different models of human skeletal muscle atrophy are required to determine the precise roles of Akt, FKHR, atrogin-1, and MuRF1 in human skeletal muscle atrophy. ALS and wild-type mice. WT 120, wild-type mice at age 120 days; ALS 90, transgenic mice at 90 days; ALS 120, transgenic mice at 120 days. Muscle mass (A) is smaller and atrogin-1 mRNA (B) is greater in the tibialas anterior (TA) muscle in ALS 90 and ALS 120 when compared with WT 120. *P < 0.05; ***P < 0.01. C) A significant negative correlation exists between TA muscle mass and atrogin-1 mRNA for all mice studied. D) Atrogin-1 protein is greater in G93A ALS when compared with the wild-type mice. *P < 0.05. Western blot image is of two representative WT 120 and ALS 90. 
